The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Pacira BioSciences Inc shares valued at $80,117 were sold by SLONIN JONATHAN on Jul 02 ’24. At $28.25 per share, SLONIN JONATHAN sold 2,836 shares. The insider’s holdings dropped to 95,557 shares worth approximately $2.1 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, WILLIAMS KRISTEN sold 7,452 shares, netting a total of over 211,488 in proceeds. Following the sale of shares at $28.38 each, the insider now holds 102,912 shares.
Before that, GAUGLER DARYL had sold 1,000 shares from its account. In a trade valued at $28,380, the Chief Operating Officer traded Pacira BioSciences Inc shares for $28.38 each. Upon closing the transaction, the insider’s holdings decreased to 1,000 shares, worth approximately $2.55 million.
As published in a research note from Barclays on July 03, 2024, Pacira BioSciences Inc [PCRX] has been rated down from an Overweight to an Equal weight and the price target has been revised to $25 from $38. As of December 20, 2023, Raymond James has initiated its “an Outperform” rating for PCRX. Earlier on August 03, 2023, TD Cowen upgraded its rating. Their new recommendation was “an Outperform” for PCRX stock which previously was a “a Market perform”.
Analyzing PCRX Stock Performance
During the last five days, there has been a drop of approximately -20.50%. Over the course of the year, Pacira BioSciences Inc shares have dropped approximately -34.94%. Shares of the company reached a 52-week high of $35.95 on 01/08/24 and a 52-week low of $20.52 on 07/02/24. A 50-day SMA is recorded $28.50, while a 200-day SMA reached $29.55. Nevertheless, trading volume fell to 1.04 million shares from 9.13 million shares the previous day.
Support And Resistance Levels for Pacira BioSciences Inc (PCRX)
According to the 24-hour chart, there is a support level at 21.19, which, if violated, would cause prices to drop to 20.71. In the upper region, resistance lies at 22.35. The next price resistance is at 23.04. RSI (Relative Strength Index) is 24.00 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -3.08, which suggests the price will decrease in the coming days. Percent R is at 87.46%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
